<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629563</url>
  </required_header>
  <id_info>
    <org_study_id>PGL11-006</org_study_id>
    <nct_id>NCT01629563</nct_id>
  </id_info>
  <brief_title>PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata</brief_title>
  <acronym>PEARLIV</acronym>
  <official_title>A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PregLem SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PregLem SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, multicentre, randomized, double-blind, parallel group, long-term study
      investigating the efficacy and safety of the 5mg and 10mg doses of PGL4001 for the treatment
      of uterine myoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target population is composed of pre-menopausal women with symptomatic uterine myoma(s)
      characterised by heavy bleeding.The main objective of this study is to assess the sustained
      efficacy and safety of long term on-off treatment with PGL4001 5 or 10mg doses on uterine
      bleeding, myoma size, pain and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses</measure>
    <time_frame>18 months study duration per subject (4 3-month intermittent treatment courses)</time_frame>
    <description>Amenorrhoea was defined as no more than 1 day of spotting within a 35 day interval. Subjects need to be in amenorrhoea at the end of all four treatment courses, i.e for at least 4x35 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Were in Amenorrhea at the End of Treatment Course 4</measure>
    <time_frame>After 18 months</time_frame>
    <description>Amenorrhoea was defined as no more than 1 day of spotting within a 35 day interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Controlled Bleeding at the End of All 4 Treatment Courses</measure>
    <time_frame>After 18 months</time_frame>
    <description>Controlled bleeding was defined as no episodes of heavy bleeding and a maximum of 8 days of bleeding during the last 56 days of a treatment course.
Subjects need to be in controlled bleeding at the end of all 4 treatment courses i.e. for at least 4x56 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Change From Baseline to End of Treatment Course 4 in the Total Volume of the 3 Largest Fibroids</measure>
    <time_frame>After 18 months</time_frame>
    <description>For the 3 largest myomas at baseline and the 3 largest myomas at the end of treatment course 4 identified by transvaginal ultrasound, length, height and depth were measured and the volume was estimated by applying the equation for the voulme of an ellipsoid (length x height x depht x π/6).
Subjects were exposed to 4 3-month intermittent courses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Change From Baseline to End of Treatment Course 4 in Quality of Life (Uterine Fibroid Symptom Severity (UFSQoL)</measure>
    <time_frame>After 18 months</time_frame>
    <description>Quality of Life was assessed using a validated questionnaire measuring uterine fibroid symptom severity (UFSQoL) where lower scores indicate fewer symtoms and where a level of 23 has been reported for healthy subject (scale 0-100).
Subjects were exposed to 4 3-month intermittent courses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Change From Baseline to End of Treatment Course 4 in Quality of Life -Uterine Fibroid Health Related Quality of Life (HRQL)</measure>
    <time_frame>18 months</time_frame>
    <description>Quality of Life was measured using a validated uterine fibroid symptom questionnaire. Total score for health related quality of Life (HRQL) range from 0 to 100 with higher scores indicating better Quality of Life.
Subjects were exposed to 4 3-month intermittent courses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Change From Baseline to End of Treatment Course 4 in Pain Using a Visual Analogue Scale (VAS)</measure>
    <time_frame>After 18 months</time_frame>
    <description>Pain was assessed using a Visual Analogue Scale (VAS) ranging from 0 to 100 with higher score indicating more severe pain.
Subjects were exposed to 4 3-month intermittent courses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Ulipristal acetate (PGL4001) 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulipristal acetate (PGL4001) 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PGL4001 5 mg</intervention_name>
    <description>PGL4001 5 mg daily administration</description>
    <arm_group_label>Ulipristal acetate (PGL4001) 5mg</arm_group_label>
    <other_name>Ulipristal Acetate, Esmya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PGL4001 10 mg</intervention_name>
    <description>PGL4001 10mg daily administration</description>
    <arm_group_label>Ulipristal acetate (PGL4001) 10mg</arm_group_label>
    <other_name>Ulipristal Acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a pre-menopausal woman between 18 and 50 years inclusive.

          -  Have a Body Mass Index (BMI) ≥ 18 and ≤ 40.

          -  Have FSH levels ≤ 20 mIU/mL

          -  Have excessive uterine bleeding due to myoma.

          -  Have regular menstrual cycles

          -  Have a myomatous uterus &lt; 16 weeks with at least one myoma ≥ 3 cm in diameter.

          -  If of childbearing potential the subject must be practicing a non-hormonal method of
             contraception.

        Exclusion Criteria:

          -  Has a history of or current uterine, cervical, ovarian or breast cancer.

          -  Has a history of or current endometrium atypical hyperplasia or adenocarcinoma.

          -  Has a known severe coagulation disorder.

          -  Has a history of or current treatment for myoma with a Selective Progesterone Receptor
             Modulator (SPRM).

          -  Has abnormal hepatic function at study entry.

          -  Has a positive pregnancy test, is nursing or planning a pregnancy during the course of
             the study.

          -  Has a current (within twelve months) problem with alcohol or drug abuse.

          -  Is currently enrolled in an investigational drug or device study or has participated
             in such a study within the last 30 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Arrigada, MD</last_name>
    <role>Study Director</role>
    <affiliation>PregLem SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc Gynécologie-Obstétrique</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège, CHR de la Citadelle Gynécologie-Obstétrique</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum ambulantni gynekologie a primarni pece</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Brno Gynekologicko - porodnická klinika</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorium SANUS</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava Gynekologicko - porodnicke oddeleni</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G-CENTRUM Olomouc s.r.o.</name>
      <address>
        <city>Olomouc</city>
        <zip>77200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Olomouc, Porodnicko-Gynekologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>77220</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Femina Sana, s.r.o.</name>
      <address>
        <city>Praha 3</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre - APHP</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat, Service de Gynécologie Obstétrique</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau Service de Gynécologie Obstétrique</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Hamburg</city>
        <zip>22359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenarztpraxis</name>
      <address>
        <city>Hessen</city>
        <zip>60322</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Frauenheilkunde, Klinische Forschung und Weiterbildung</name>
      <address>
        <city>Magdeburg</city>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rethy Pal Korhaz és Rendelointezet Szuleszeti es Nogyogyaszati Osztaly</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution Robert Karoly Maganklinika</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Anna Szuleszeti, Nogyogyaszati es Ultrahang Maganrendelo</name>
      <address>
        <city>Debrecen</city>
        <zip>4024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Korhaz Szuleszeti es Nogyogyaszati Osztaly</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szuleszeti es Nogyogyaszati Osztaly</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandor Dent Bt.</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Ostetricia e Ginecologia, Università degli Studi di Catanzaro &quot;Magna Graecia&quot;</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario &quot;Agostino Gemelli&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga 1. hospital</name>
      <address>
        <city>Riga</city>
        <zip>1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvian Medical Marine Center</name>
      <address>
        <city>Riga</city>
        <zip>LV-1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Company &quot;ARS&quot;</name>
      <address>
        <city>Riga</city>
        <zip>LV-1010</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saules Family Medicine Center</name>
      <address>
        <city>Kaunas</city>
        <zip>49449</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine Centre&quot;Seimos Gydytojas&quot;</name>
      <address>
        <city>Vilnius</city>
        <zip>01118</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic &quot;Maxmeda&quot;</name>
      <address>
        <city>Vilnius</city>
        <zip>03225</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic &quot;Kardiolita&quot;</name>
      <address>
        <city>Vilnius</city>
        <zip>05263</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical SANA SRL</name>
      <address>
        <city>Bucuresti</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Medical Center SRL Obstetrica-Ginecologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>011426</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Medical Center SRL Obstetrica Ginecologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>012064</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Dr. I.Cantacuzino sectia Obstetrica-Ginecologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical EUROMED SRL, Departamentul de Obtetrica/Ginecologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>020762</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Obstetrica</name>
      <address>
        <city>Iasi</city>
        <zip>700398</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv City Perinatal Center Gynaecological Department #1</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Maternity Hospital #1&quot; City Center of family planning</name>
      <address>
        <city>Odessa</city>
        <zip>65039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternity Hospital#4 Department of Gynaecology</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69065</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRC Centre for Reproductive Health University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Middlesex University Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health, Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR47UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2012</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>August 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulipristal acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ulipristal Acetate (PGL4001) 5mg</title>
          <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
        </group>
        <group group_id="P2">
          <title>Ulipristal Acetate (PGL4001) 10mg</title>
          <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="223">2 subjects randomised to 10mg received 5mg treatment in error (FAS 1: 10mg, Safety Set: 5mg)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Treatment Course 2</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Treatment Course 3</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Treatment Course 4</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of return of menses</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set 1(all subjects who received study treatment at least once for treatment course 1) (treament group as randomised)</population>
      <group_list>
        <group group_id="B1">
          <title>Ulipristal Acetate (PGL4001) 5mg</title>
          <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
        </group>
        <group group_id="B2">
          <title>Ulipristal Acetate (PGL4001) 10mg</title>
          <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="228"/>
            <count group_id="B2" value="223"/>
            <count group_id="B3" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="5.4"/>
                    <measurement group_id="B2" value="41.4" spread="5.1"/>
                    <measurement group_id="B3" value="41.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total volume of the 3 largest myoma</title>
          <description>total volume of the three largest myomas (length, height and depth measured using transvaginal ultrasound, volume estimated by applying the equation for the volume of an ellipsoid (length × height × depth × π/6))</description>
          <units>cm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" lower_limit="24.0" upper_limit="94.2"/>
                    <measurement group_id="B2" value="43.6" lower_limit="27.3" upper_limit="117.3"/>
                    <measurement group_id="B3" value="43.3" lower_limit="25.1" upper_limit="102.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Assessment (Visual Analogue Scale)</title>
          <description>Pain was assessed using a visual analogue scale (VAS) ranging from 0 to 100 with higher score indicating more severe pain.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" lower_limit="15.6" upper_limit="62"/>
                    <measurement group_id="B2" value="43.0" lower_limit="19.0" upper_limit="67.0"/>
                    <measurement group_id="B3" value="40.5" lower_limit="17.0" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uterine Fibroid Symptom Quality of Life Questionnaire</title>
          <description>Quality of Life was assessed using a validated questionnaire measuring uterine fibroid sympotom severity (UFSQoL) where lower scores indicate fewer symptoms and where a level of 23 has been reported for healthy subjects (scale 0-100).
Total score for health related QoL (HRQL) ranges from 0 to 100 with higher score indicating better quality of Life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Symptom Severity (UFSQoL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" lower_limit="37.5" upper_limit="62.5"/>
                    <measurement group_id="B2" value="50.0" lower_limit="37.5" upper_limit="62.5"/>
                    <measurement group_id="B3" value="50.0" lower_limit="37.5" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health related Quality of Life (HRQL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" lower_limit="42.2" upper_limit="75.9"/>
                    <measurement group_id="B2" value="55.2" lower_limit="41.4" upper_limit="71.6"/>
                    <measurement group_id="B3" value="56.0" lower_limit="41.4" upper_limit="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses</title>
        <description>Amenorrhoea was defined as no more than 1 day of spotting within a 35 day interval. Subjects need to be in amenorrhoea at the end of all four treatment courses, i.e for at least 4x35 days.</description>
        <time_frame>18 months study duration per subject (4 3-month intermittent treatment courses)</time_frame>
        <population>Full Analysis Set 1 (subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate (PGL4001) 5mg</title>
            <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
          </group>
          <group group_id="O2">
            <title>Ulipristal Acetate (PGL4001) 10mg</title>
            <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses</title>
          <description>Amenorrhoea was defined as no more than 1 day of spotting within a 35 day interval. Subjects need to be in amenorrhoea at the end of all four treatment courses, i.e for at least 4x35 days.</description>
          <population>Full Analysis Set 1 (subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                    <measurement group_id="O2" value="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Were in Amenorrhea at the End of Treatment Course 4</title>
        <description>Amenorrhoea was defined as no more than 1 day of spotting within a 35 day interval.</description>
        <time_frame>After 18 months</time_frame>
        <population>Full Analysis Set 1 (all subjects who received study treatment once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate (PGL4001) 5mg</title>
            <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
          </group>
          <group group_id="O2">
            <title>Ulipristal Acetate (PGL4001) 10mg</title>
            <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Were in Amenorrhea at the End of Treatment Course 4</title>
          <description>Amenorrhoea was defined as no more than 1 day of spotting within a 35 day interval.</description>
          <population>Full Analysis Set 1 (all subjects who received study treatment once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                    <measurement group_id="O2" value="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Controlled Bleeding at the End of All 4 Treatment Courses</title>
        <description>Controlled bleeding was defined as no episodes of heavy bleeding and a maximum of 8 days of bleeding during the last 56 days of a treatment course.
Subjects need to be in controlled bleeding at the end of all 4 treatment courses i.e. for at least 4x56 days.</description>
        <time_frame>After 18 months</time_frame>
        <population>Full analysis set 1 (all subject who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate (PGL4001) 5mg</title>
            <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
          </group>
          <group group_id="O2">
            <title>Ulipristal Acetate (PGL4001) 10mg</title>
            <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Controlled Bleeding at the End of All 4 Treatment Courses</title>
          <description>Controlled bleeding was defined as no episodes of heavy bleeding and a maximum of 8 days of bleeding during the last 56 days of a treatment course.
Subjects need to be in controlled bleeding at the end of all 4 treatment courses i.e. for at least 4x56 days.</description>
          <population>Full analysis set 1 (all subject who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                    <measurement group_id="O2" value="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Change From Baseline to End of Treatment Course 4 in the Total Volume of the 3 Largest Fibroids</title>
        <description>For the 3 largest myomas at baseline and the 3 largest myomas at the end of treatment course 4 identified by transvaginal ultrasound, length, height and depth were measured and the volume was estimated by applying the equation for the voulme of an ellipsoid (length x height x depht x π/6).
Subjects were exposed to 4 3-month intermittent courses.</description>
        <time_frame>After 18 months</time_frame>
        <population>Full Analysis Set 1 (all subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate (PGL4001) 5mg</title>
            <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
          </group>
          <group group_id="O2">
            <title>Ulipristal Acetate (PGL4001) 10mg</title>
            <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Change From Baseline to End of Treatment Course 4 in the Total Volume of the 3 Largest Fibroids</title>
          <description>For the 3 largest myomas at baseline and the 3 largest myomas at the end of treatment course 4 identified by transvaginal ultrasound, length, height and depth were measured and the volume was estimated by applying the equation for the voulme of an ellipsoid (length x height x depht x π/6).
Subjects were exposed to 4 3-month intermittent courses.</description>
          <population>Full Analysis Set 1 (all subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
          <units>percentage of change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.0" lower_limit="-85.6" upper_limit="-35.1"/>
                    <measurement group_id="O2" value="-70.4" lower_limit="-88.0" upper_limit="-41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Change From Baseline to End of Treatment Course 4 in Quality of Life (Uterine Fibroid Symptom Severity (UFSQoL)</title>
        <description>Quality of Life was assessed using a validated questionnaire measuring uterine fibroid symptom severity (UFSQoL) where lower scores indicate fewer symtoms and where a level of 23 has been reported for healthy subject (scale 0-100).
Subjects were exposed to 4 3-month intermittent courses.</description>
        <time_frame>After 18 months</time_frame>
        <population>Full Analysis Set 1 (all subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate (PGL4001) 5mg</title>
            <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
          </group>
          <group group_id="O2">
            <title>Ulipristal Acetate (PGL4001) 10mg</title>
            <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Change From Baseline to End of Treatment Course 4 in Quality of Life (Uterine Fibroid Symptom Severity (UFSQoL)</title>
          <description>Quality of Life was assessed using a validated questionnaire measuring uterine fibroid symptom severity (UFSQoL) where lower scores indicate fewer symtoms and where a level of 23 has been reported for healthy subject (scale 0-100).
Subjects were exposed to 4 3-month intermittent courses.</description>
          <population>Full Analysis Set 1 (all subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
          <units>percentage of change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.25" lower_limit="-46.88" upper_limit="-12.50"/>
                    <measurement group_id="O2" value="-28.13" lower_limit="-43.75" upper_limit="-18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Change From Baseline to End of Treatment Course 4 in Quality of Life -Uterine Fibroid Health Related Quality of Life (HRQL)</title>
        <description>Quality of Life was measured using a validated uterine fibroid symptom questionnaire. Total score for health related quality of Life (HRQL) range from 0 to 100 with higher scores indicating better Quality of Life.
Subjects were exposed to 4 3-month intermittent courses.</description>
        <time_frame>18 months</time_frame>
        <population>Full Analysis Set 1 (all subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate (PGL4001) 5mg</title>
            <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
          </group>
          <group group_id="O2">
            <title>Ulipristal Acetate (PGL4001) 10mg</title>
            <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Change From Baseline to End of Treatment Course 4 in Quality of Life -Uterine Fibroid Health Related Quality of Life (HRQL)</title>
          <description>Quality of Life was measured using a validated uterine fibroid symptom questionnaire. Total score for health related quality of Life (HRQL) range from 0 to 100 with higher scores indicating better Quality of Life.
Subjects were exposed to 4 3-month intermittent courses.</description>
          <population>Full Analysis Set 1 (all subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
          <units>percentage of change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.69" lower_limit="6.47" upper_limit="35.34"/>
                    <measurement group_id="O2" value="15.52" lower_limit="5.17" upper_limit="37.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Change From Baseline to End of Treatment Course 4 in Pain Using a Visual Analogue Scale (VAS)</title>
        <description>Pain was assessed using a Visual Analogue Scale (VAS) ranging from 0 to 100 with higher score indicating more severe pain.
Subjects were exposed to 4 3-month intermittent courses.</description>
        <time_frame>After 18 months</time_frame>
        <population>FAS1 (all subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Ulipristal Acetate (PGL4001) 5mg</title>
            <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
          </group>
          <group group_id="O2">
            <title>Ulipristal Acetate (PGL4001) 10mg</title>
            <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Change From Baseline to End of Treatment Course 4 in Pain Using a Visual Analogue Scale (VAS)</title>
          <description>Pain was assessed using a Visual Analogue Scale (VAS) ranging from 0 to 100 with higher score indicating more severe pain.
Subjects were exposed to 4 3-month intermittent courses.</description>
          <population>FAS1 (all subjects who received study treatment at least once for treatment course 1) (subjects with missing values were excluded from analysis)</population>
          <units>percentage of change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" lower_limit="-46.1" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-23.0" lower_limit="-52.0" upper_limit="-1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse events were reported where the start date was on or after the first dose of study medication, up to the end of study follow-up (21 months on average).Other Adverse Events are summarised as on-treatment TEAEs.</time_frame>
      <desc>2 subjects randomised to Ulipristal acetate 10 mg received 5 mg by mistake. They are included in the safety set according to treatment received.
On-treatment TEAEs are events where the start date was on or after the first dose of study medication, up to and including 7 days after the last dose of study medication within each treatment course.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ulipristal Acetate (PGL4001) 5mg</title>
          <description>PGL4001 5 mg: PGL4001 5 mg daily administration</description>
        </group>
        <group group_id="E2">
          <title>Ulipristal Acetate (PGL4001) 10mg</title>
          <description>PGL4001 10 mg: PGL4001 10mg daily administration</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Iron deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arteriospam coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>accidental death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>homicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>castleman's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urethral stenesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>breast hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>aneamia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>hot flush</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>breast pain/breast tenderness/breast disconfort</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall submit to sponsor results communication for review 60 days prior to publication submission. If in the sponsor judgement, publication at a given time would hinder the sponsor's IP development, PI shall consider modifying the publication schedule. PI agrees to delete information identified by sponsor as confidential or defer publication to permit filing of patent application by the sponsor. Publication based on 1 site results shall not be made before the first muti-centre publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Pablo Arriagada</name_or_title>
      <organization>PregLem</organization>
      <phone>0041228840355</phone>
      <email>info@preglem.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

